Skip to main content
Isomer
  1. Home
  2. Automated
  3. List of product information
  4. OCTREOSCAN FOR INJECTION [SIN11244P]

OCTREOSCAN FOR INJECTION [SIN11244P]

Active ingredients: OCTREOSCAN FOR INJECTION

Last updated 26 October 2025

Product Info

OCTREOSCAN FOR INJECTION

[SIN11244P]

Product information

Active Ingredient and Strength

INDIUM (IN 111) CHLORIDE - 122 MBQ/1.1 ML (IN VIAL A)
PENTETREOTIDE - 10 MCG/VIAL (IN VIAL B)

Dosage Form

INJECTION, POWDER, FOR SOLUTION

Manufacturer and Country

CURIUM NETHERLANDS B.V. - NETHERLANDS

Registration Number

SIN11244P

Licence Holder

QT INSTRUMENTS (S) PTE LTD

Forensic Classification

PRESCRIPTION ONLY MEDICINES

Anatomical Therapeutic Chemical (ATC) code

NA

I. Indications
111In pentetreotide specifically binds to receptors for somatostatin.
OctreoScan is indicated for use as adjunct in the diagnosis and management of receptor bearing gastro-entero-pancreatic neuroendocrine (GEP) tumours and carcinoid tumours, by aiding in their localisation. Tumours which do not bear receptors will not be visualised.
In a number of patients suffering from GEP or carcinoid tumours the receptor density is insufficient to allow visualisation with OctreoScan. Notably in approximately 50% of patients suffering from insulinoma the tumour cannot be visualised.

II. Posology and method of administration
The dose for planar scintigraphy is 110 MBq in one single intravenous injection. Careful administration is necessary to avoid paravasal deposition of activity. For single photon emission tomography the dose depends on the available equipment. In general, an activity dose of 110 to 220 MBq in one single intravenous injection should be sufficient. No special dosage regimen for elderly patients is required.

There is limited experience on administrations in paediatric patients, but when the use in a child is considered to be necessary, the amount of activity administered should be reduced according to standard body weight or body surface calculations. A practical approach is to adopt the recommendations of the Paediatric Task Group, European Association of Nuclear Medicine.

Table caption

3 kg = 0.1

22 kg = 0.50

42 kg = 0.78

4 kg = 0.14

24 kg = 0.53

44 kg = 0.80

6 kg = 0.19

26 kg = 0.56

46 kg = 0.82

8 kg = 0.23

28 kg = 0.58

48 kg = 0.85

10 kg = 0.27

30 kg = 0.62

50 kg = 0.88

12 kg = 0.32

32 kg = 0.65

52-54 kg = 0.90

14 kg = 0.36

34 kg = 0.68

56-58 kg = 0.92

16 kg = 0.40

36 kg = 0.71

60-62 kg = 0.96

18 kg = 0.44

38 kg = 0.73

64-66 kg = 0.98

20 kg = 0.46

40 kg = 0.76

68 kg = 0.99

Scintigraphy takes place approx. 24 hours after administration. When activity in the abdomen is observed at 24 hours which cannot be interpreted with certainty as uptake in tumour or activity in bowel contents, scintigraphy should be repeated at 48 hours. In some cases, scintigraphy after 4 hours gives acceptable results. Physiologic uptake occurs in spleen, liver, kidneys and bladder. Thyroid, pituitary and intestines are visible in most patients.

III. Contraindications
No specific contraindications have been identified.